Team27 Sleep Easy is up and ready to go for the Rothberg Catalyzer #CatalyzeratPenn #RothbergCatalyzeratPenn

No sleep ahead for team Sleep Easy! Popping in at the team check-in before the night ahead #CatalyzeratPenn

14hrs after starting T27 has the artificial baroreceptor successfully measuring pressures in a model, proof of concept, hemodynamic system #CatalyzeratPenn

Team Sleep Easy ready to get some shut eye at the late (early?) hour of 4:08am #CatalyzeratPenn

T27 presenting the Artificial Baroreceptor at the Rothberg Catalyzer #CatalyzeratPenn Thx to @FSilvestryMD for inspiring a Cards interest in penn med students!

Patients with #COVID19 admitted to the ICU were 10X more likely to have a significant heart arrhythmias than others hospitalized, from a series of 700 patients Penn Medicine heartrhythmjournal.com/article/S1547-… HeartRhythm by Anjali Bhatla and colleagues

We are excited to announce our $4m seed round led by a16z to reimagine cancer treatment decisions with artificial intelligence! valarlabs.medium.com/valar-labs-rei…

1st #bladdercancer drug targeting a cancer-driving gene #mutation hasn't been given often to patients despite showing efficacy. The study in JAMA Oncology led by Ronac Mamtani, Erica L. Carpenter, MBA, PhD, Vivek Nimgaonkar, & Rebecca Hubbard conveys essential use: spr.ly/6010zJSiM.

Exciting news! Valar Labs is proud to announce #Vesta, the first histology-based test for predicting response to #BCG in #BladderCancer. Press Release: bit.ly/44q09CF